💨 Abstract

The FDA is changing its approach to COVID-19 vaccine approvals, focusing on individuals aged 65 and above, and those with underlying health conditions. Future vaccines will be available to these groups while requiring more rigorous evidence for general and younger populations. This shift, outlined by Dr. Vinay Prasad and Dr. Marty Makary, aims to ensure rapid availability for high-risk individuals and restore public confidence in vaccines. Notably, Moderna supports the change, while other experts like Dr.

Courtesy: wtop.com